Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and

Dylan M Johnson1,2, Beatrice Cubitt3, Tia L Pfeffer2,4

  • 1Department of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville, KY 40202, USA.

Viruses
|February 12, 2021
PubMed

Insights

Defective interfering particles (DIPs) derived from a Lassa fever vaccine candidate (ML29) significantly inhibit viral replication and show reduced pathogenicity in animal models. These findings highlight DIPs as promising tools for developing novel antiviral biologics.

Area of Science:

  • Virology
  • Immunology
  • Biotechnology

Background:

  • Defective interfering particles (DIPs) are naturally occurring viral variants that interfere with standard virus replication.
  • DIPs play crucial roles in modulating viral infection outcomes and innate immune responses.
  • Mammarenaviruses, including Lassa virus (LASV), are significantly impacted by DIPs during infection.

Purpose of the Study:

  • To investigate the generation and biological impact of DIPs from the Lassa fever vaccine candidate ML29.
  • To assess the antiviral potential of DIP-enriched ML29 against other viruses.
  • To evaluate the safety and efficacy of DIP-enriched ML29 in preclinical animal models.

Main Methods:

  • Infection of cell cultures with ML29 at varying multiplicities of infection (MOI) to generate and detect DIPs.
  • Assessment of ML29-induced DIPs' ability to inhibit viral replication using a reporter virus system (r3LCMV-GFP/GFP).
  • Preclinical evaluation of DIP-enriched ML29 in immunocompetent and STAT-1 knockout mice, and Hartley guinea pigs, monitoring for pathogenicity and hearing loss.

Main Results:

  • L-derived truncated RNA species, indicative of DIPs, were detected in ML29-infected cells.
  • ML29-persistently infected cells exhibited strong inhibition of GFP expression from a reporter virus, dependent on passage history.
  • DIP-enriched ML29 demonstrated significant attenuation in mice and guinea pigs, with no observed hearing abnormalities in a Lassa fever-associated hearing loss model.

Conclusions:

  • ML29 generates defective interfering particles (DIPs) that possess potent antiviral activity against other viruses.
  • DIP-enriched ML29 exhibits substantial attenuation and safety in preclinical models, including those relevant to Lassa fever sequelae.
  • These findings support the development of DIP-based biologics for targeting diverse and evolving viral infections.